Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
F	O
Service:	O
MEDICINE	O
Allergies:	O
Levaquin	O
Attending:	O
___	O
___	O
Complaint:	O
right	O
eye	O
vision	B-Visual_impairment
loss	B-Visual_impairment
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
CTA	O
HEAD	O
History	O
of	O
Present	O
Illness:	O
Mrs.	O
___	O
is	O
a	O
___	O
yo	O
woman	O
with	O
a	O
history	O
of	O
DVT/PE	O
s/p	O
IVC	O
filter,	O
HTN,	O
bronchitis,	O
pyelonephritis	B-Urinary_tract_infection
s/p	O
renal	O
drain	O
sent	O
from	O
Mass	O
Eye	O
and	O
ear	O
Clinic	O
for	O
R	O
eye	O
visual	B-Visual_impairment
loss	B-Visual_impairment
since	O
4pm	O
yesterday.	O
No	O
eye	O
pain.	O
L	O
eye	O
no	B-Visual_impairment
change	B-Visual_impairment
in	B-Visual_impairment
vision.	B-Visual_impairment
No	O
weakness,	O
numbness.	O
Went	O
to	O
Mass	O
Eye	O
and	O
ear	O
with	O
concern	O
for	O
R	O
central	O
retinal	B-Visual_impairment
artery	B-Visual_impairment
occlusion.	B-Visual_impairment
Patient	O
with	O
cherry	O
red	O
spot	O
on	O
dilated	O
opthalmic	O
exam	O
per	O
clinic	O
note.	O
Was	O
sent	O
back	O
to	O
___,	O
than	O
to	O
___	O
ER	O
for	O
evaluation.	O
Of	O
note,	O
patient	O
was	O
at	O
___	O
after	O
discharge	O
from	O
___	O
___	O
for	O
pyelo	B-Urinary_tract_infection
requiring	O
nephrostomy	O
tube.	O
In	O
ER,	O
Patient	O
in	O
NSR	O
with	O
no	O
obvious	O
source,	O
Optho	O
called,	O
do	O
not	O
need	O
to	O
see	O
patient	O
as	O
>24	O
hours	O
and	O
outside	O
of	O
treatment	O
window	O
but	O
recommend	O
urgent	O
cardiovascular	O
work	O
up	O
to	O
find	O
source	O
to	O
prevent	O
more	O
sequelae	O
(Triage	O
Vitals:97.9	O
108	O
143/68	O
18	O
98	O
)	O
Meds	O
Given:ASA,	O
heparin(INR	O
sub	O
theraputic).	O
ROS:	O
-Constitutional:	O
[x]WNL	O
[]Weight	I-Visual_impairment
loss	B-Visual_impairment
[]Fatigue/Malaise	O
[]Fever	O
[]Chills/Rigors	O
[]Nightweats	O
[]Anorexia	O
-Cardiac:	O
[x]WNL	O
[]Chest	O
pain	O
[]Palpitations	O
___	O
edema	O
[]Orthopnea/PND	O
[]DOE	O
-Respiratory:	O
[x]WNL	O
[]SOB	O
[]Pleuritic	O
pain	O
[]Hemoptysis	O
[]Cough	O
-Gastrointestinal:	O
[x]WNL	O
[]Nausea	O
[]Vomiting	O
[]Abdominal	O
pain	O
[]Abdominal	O
Swelling	O
[]Diarrhea	O
[]Constipation	I-Constipation
[]Hematemesis	I-Upper_gastrointestinal_haemorrhage
[]Hematochezia	I-Lower_gastrointestinal_haemorrhage
[]Melena	I-Upper_gastrointestinal_haemorrhage
-GU:	O
has	O
left	O
renal	O
drain	O
after	O
last	O
episode	O
of	O
pyelo.	B-Urinary_tract_infection
No	O
pain	O
at	O
site.	O
-Neurological:	O
[	O
]WNL	O
[]Numbness	O
of	O
extremities	O
[]Weakness	O
of	O
extremities	O
[]Parasthesias	O
[]Dizziness/Lightheaded	O
[]Vertigo	O
[]Confusion	I-Delirium
[]Headache	O
Past	O
Medical	O
History:	O
chronic	O
bronchitis	O
hypertension	O
osteoarthritis	O
of	O
right	O
hip	O
high	O
cholesterol	O
PE	O
s/p	O
IVC	O
filter	O
placement	O
___	O
recurrent	O
UTI's	B-Urinary_tract_infection
Social	O
History:	O
___	O
Family	O
History:	O
no	O
fhx	O
of	O
stroke	O
Physical	O
Exam:	O
VS:	O
T	O
98.8	O
P	O
79	O
BP	O
140/70	O
RR	O
20	O
O2	O
95%RA	O
Gen:	O
no	O
acute	O
distress,	O
awake,	O
alert	O
Skin:	O
warm	O
to	O
touch,	O
no	O
apparent	O
rashes.	O
HEENT:	O
No	O
conjunctival	O
pallor,	O
no	O
scleral	O
jaundice,	O
OP	O
clear,	O
no	O
cervical	O
LAD,	O
no	O
palpable	O
thyroid	O
nodules.	O
No	O
temporal	O
artery	O
tenderness,	O
TA	O
pulse	O
wnl.	O
CV:	O
RRR	O
III/VI	O
late	O
peaking	O
systolic	O
murmur	O
at	O
RUSB	O
with	O
deminished	O
S2	O
pulses	O
2+	O
throughout,	O
Noperipheral	O
edema	O
Lungs:	O
clear	O
to	O
auscultation	O
Abd:	O
soft,	O
NT,	O
normal	O
BS,	O
nephrostomy	O
in	O
place,	O
site	O
clean	O
and	O
dry	O
w/o	O
erythema	O
Ext:	O
No	O
C/C/E	O
Neuro:	O
strength	O
and	O
sensation	O
intact	O
bilaterally,	O
CN	O
intact.	O
Pertinent	O
Results:	O
Admission	O
Labs:	O
___	O
06:00PM	O
Na	O
140	O
/	O
K	O
4.6	O
/	O
Cl	O
105	O
/	O
CO2	O
24	O
/	O
BUN	O
6	O
/	O
Cr	O
.6	O
/	O
BG	O
84	O
WBC	O
9.5	O
/	O
Hct	O
35	O
/	O
Plt	O
493	O
N	O
66	O
/	O
Bands	O
2	O
/	O
L	O
14	O
/	O
M	O
4	O
/	O
B	O
0	O
INR	O
1.5	O
/	O
PTT	O
26.6	O
Discharge	O
Labs:	O
___	O
Na	O
143	O
/	O
K	O
4.3	O
/	O
Cl	O
108	O
/	O
CO2	O
29	O
/	O
BUN	O
10	O
/	O
Cr	O
.7	O
/	O
BG	O
88	O
WBC	O
10.3	O
/	O
Hct	O
31.1	O
/	O
Plt	O
388	O
INR	O
1.6	O
/	O
PTT	O
31.1	O
Studies:	O
Echo	O
___	O
No	O
echocardiographic	O
source	O
of	O
embolism	O
identified.	O
Normal	O
global	O
biventricular	O
systolic	O
function.	O
Technically	O
suboptimal	O
to	O
exclude	O
focal	O
wall	O
motion	O
abnormality.	O
CXR	O
___	O
Right	O
PICC	O
tip	O
is	O
in	O
the	O
mid	O
to	O
lower	O
SVC.	O
There	O
is	O
mild	O
cardiomegaly.	O
Blunting	O
of	O
the	O
right	O
CP	O
angle	O
is	O
of	O
a	O
long	O
chronicity	O
related	O
to	O
small	O
pleural	O
effusion	O
or	O
pleural	O
thickening.	O
There	O
is	O
no	O
pneumothorax.	O
Minimal	O
interstitial	O
abnormalities	O
and	O
small	O
lung	O
nodules	O
are	O
in	O
the	O
bases	O
bilaterally	O
and	O
in	O
the	O
mid	O
left	O
lung.	O
This	O
is	O
of	O
a	O
unknown	O
chronicity	O
or	O
etiology.	O
Carotid	O
US	O
___	O
Minimal	O
atherosclerotic	O
plaque	O
at	O
the	O
origin	O
of	O
the	O
ICA	O
bilaterally	O
but	O
without	O
evidence	O
of	O
significant	O
stenoses.	O
CTA	B-Intracranial_haemorrhage
Head	B-Intracranial_haemorrhage
___	O
-	O
1.	O
No	O
acute	O
intracranial	B-Intracranial_haemorrhage
process,	O
with	O
extensive	O
chronic	O
small	O
vessel	O
ischemic	O
disease.	O
2.	O
Normal	O
CTA	O
of	O
the	O
head,	O
without	O
evidence	O
of	O
occlusion,	O
or	O
aneurysm	O
formation.	O
3.	O
Hypodensity	O
in	O
the	O
suprasellar	O
cistern	O
could	O
reflect	O
normal	O
variant.	O
However,	O
a	O
pituitary	O
microadenoma	O
cannot	O
be	O
entirely	O
excluded.	O
If	O
clinically	O
indicated,	O
this	O
can	O
be	O
further	O
evaluated	O
with	O
MR.	O
___	O
___	O
-	O
Sinus	O
rhythm.	O
Atrial	O
ectopy.	O
No	O
previous	O
tracing	O
available	O
for	O
comparison.	O
Brief	O
Hospital	O
Course:	O
Mrs.	O
___	O
is	O
a	O
___	O
yo	O
woman	O
w/	O
h/o	O
DVT/PE	O
s/p	O
IVC	O
filter	O
and	O
on	O
coumadin,	O
HTN,	O
bronchitis	O
who	O
presents	O
for	O
cardiac	O
work	O
up	O
after	O
sudden	O
vision	B-Visual_impairment
loss	B-Visual_impairment
in	O
the	O
right	O
eye	O
due	O
to	O
CRAO	O
on	O
___.	O
1.	O
Retinal	B-Visual_impairment
artery	B-Visual_impairment
occlusion:	B-Visual_impairment
Unfortunately	O
patient	O
presented	O
to	O
the	O
OSH	O
outside	O
treatment	O
window	O
for	O
thrombolytic	O
therapy.	O
Per	O
report,	O
this	O
retinal	B-Visual_impairment
artery	B-Visual_impairment
occlusion	B-Visual_impairment
occurred	O
while	O
therapeutic	O
on	O
coumadin.	O
In	O
addition	O
to	O
the	O
right	O
eye	O
vision	B-Visual_impairment
loss,	B-Visual_impairment
she	O
has	O
no	O
other	O
focal	O
neuro	O
abnormalities.	O
Cardiac	O
workup	O
for	O
source	O
of	O
thromboemboli	O
was	O
pursued	O
at	O
___	O
and	O
no	O
source	O
was	O
identified.	O
Lipid	O
panel	O
wnl,	O
ECHO	O
showed	O
no	O
PFO.	O
ESR	O
and	O
CRP	O
elevated	O
likely	O
due	O
to	O
recent	O
pyelo,	B-Urinary_tract_infection
no	O
evidence	O
of	O
temporal	O
arteritis.	O
Carotid	O
duplex	O
U/S	O
showed	O
mild	O
athero	O
but	O
no	O
significant	O
stenosis.	O
The	O
formal	O
read	O
of	O
her	O
CTA	O
demonstrated	O
chronic	O
ischemic	O
changes	O
but	O
no	O
acute	O
infarct.	O
CTA	O
head	O
was	O
notable	O
only	O
for	O
a	O
hypodensity	O
in	O
the	O
pituitary	O
with	O
further	O
discussion	O
below.	O
She	O
was	O
monitored	O
on	O
telemetry	O
without	O
events.	O
She	O
was	O
initially	O
continued	O
on	O
heparin	O
drip	O
for	O
subtherapeutic	O
INR,	O
and	O
hematology	O
was	O
consulted	O
for	O
advice	O
regarding	O
appropriate	O
target	O
dose	O
given	O
thromboemboli	O
while	O
anticoagulated.	O
They	O
recommended	O
that	O
patient	O
be	O
switched	O
from	O
coumadin	O
to	O
lovenox	O
for	O
anticoagulation	O
as	O
patient	O
appeared	O
to	O
have	O
developed	O
central	O
retinal	B-Visual_impairment
artery	B-Visual_impairment
occlusion	B-Visual_impairment
while	O
anticoagulated.	O
She	O
was	O
also	O
continued	O
on	O
ASA	O
and	O
statin.	O
She	O
should	O
be	O
continued	O
on	O
lovenox	O
therapy	O
until	O
she	O
follows	O
up	O
with	O
the	O
___	O
clinic.	O
She	O
will	O
also	O
need	O
follow	O
up	O
with	O
Dr.	O
___	O
at	O
___	O
in	O
1	O
month.	O
.	O
2.	O
Anemia	O
-	O
Patient's	O
hct	O
remained	O
stable	O
between	O
___.	O
Iron	O
studies	O
revealed	O
low	O
iron,	O
TIBC	O
and	O
high	O
ferritin,	O
consistent	O
with	O
anemia	O
of	O
chronic	O
inflammation.	O
.	O
3.	O
Recent	O
Pyelonephritis	B-Urinary_tract_infection
Patient	O
has	O
a	O
history	O
of	O
MRSA	O
in	O
urine	O
at	O
OSH	O
and	O
required	O
left-sided	O
nephrostomy	O
tube	O
placement.	O
She	O
completed	O
course	O
of	O
IV	O
vancomycin	O
at	O
rehab	O
and	O
remained	O
asymptomatic.	O
While	O
at	O
___,	O
she	O
remained	O
afebrile,	O
asymptomatic,	O
and	O
her	O
nephrostomy	O
tube	O
sites	O
continued	O
to	O
drain	O
clear	O
urine.	O
Per	O
patient	O
report,	O
she	O
has	O
a	O
follow-up	O
appointment	O
with	O
the	O
urology	O
department	O
at	O
___	O
on	O
___	O
for	O
further	O
evaluation	O
of	O
her	O
nephrostomy	O
tubes	O
and	O
for	O
consideration	O
of	O
a	O
nephrectomy.	O
Of	O
note,	O
urine	O
cultures	O
drawn	O
at	O
___	O
on	O
___	O
were	O
found	O
to	O
have	O
20,000	O
colonies	O
of	O
VRE.	O
Given	O
that	O
patient	O
has	O
remained	O
asymptomatic,	O
afebrile,	O
and	O
without	O
leukocytosis,	O
decision	O
was	O
made	O
to	O
not	O
treat	O
for	O
this	O
culture	O
result.	O
.	O
4.	O
Bronchitis	O
-	O
She	O
was	O
continued	O
on	O
her	O
home	O
regimen	O
of	O
flonase	O
and	O
cough	O
suppressants.	O
.	O
5.	O
GERD	O
-	O
She	O
was	O
continued	O
on	O
her	O
home	O
regimen	O
of	O
pantoprazole.	O
.	O
6.	O
HTN	O
-	O
She	O
was	O
continued	O
on	O
her	O
home	O
regimen	O
of	O
lopressor,	O
amlodipine,	O
and	O
losartan.	O
.	O
7.	O
Pituitary	O
Abnormality	O
Patient	O
had	O
CTA	O
head	O
to	O
evaluate	O
source	O
of	O
blood	O
clot	O
for	O
retinal	B-Visual_impairment
artery	B-Visual_impairment
occlusion.	B-Visual_impairment
CTA	O
head	O
did	O
not	O
demonstrate	O
a	O
source	O
of	O
clot	O
but	O
did	O
note	O
"Hypodensity	O
in	O
the	O
suprasellar	O
cistern	O
could	O
reflect	O
normal	O
variant.	O
However,	O
a	O
pituitary	O
microadenoma	O
cannot	O
be	O
entirely	O
excluded."	O
Patient	O
remained	O
asymptomatic	O
during	O
her	O
hospitalization,	O
and	O
we	O
would	O
recommend	O
continued	O
monitoring	O
as	O
an	O
outpatient.	O
Medications	O
on	O
Admission:	O
coumadin	O
___	O
per	O
day	O
lopressor	O
12.5	O
bid	O
flonase	O
2	O
puffs	O
bid	O
cozaar	O
100	O
daily	O
amlodipine	O
5	O
daily	O
simvastatin	O
20	O
daily	O
colace	O
100	O
bid	O
fosamax	O
70	O
weekly	O
protonix	O
40	O
qdialy	O
robitussin	O
10	O
q4	O
standing	O
Discharge	O
Medications:	O
1.	O
Metoprolol	O
Tartrate	O
25	O
mg	O
Tablet	O
Sig:	O
0.5	O
Tablet	O
PO	O
BID	O
(2	O
times	O
a	O
day).	O
2.	O
Fluticasone	O
50	O
mcg/Actuation	O
Spray,	O
Suspension	O
Sig:	O
Two	O
(2)	O
Spray	O
Nasal	O
BID	O
(2	O
times	O
a	O
day).	O
3.	O
Losartan	O
50	O
mg	O
Tablet	O
Sig:	O
Two	O
(2)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
4.	O
Amlodipine	O
5	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
5.	O
Simvastatin	O
10	O
mg	O
Tablet	O
Sig:	O
Two	O
(2)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
6.	O
Pantoprazole	O
40	O
mg	O
Tablet,	O
Delayed	O
Release	O
(E.C.)	O
Sig:	O
One	O
(1)	O
Tablet,	O
Delayed	O
Release	O
(E.C.)	O
PO	O
Q24H	O
(every	O
24	O
hours).	O
7.	O
Guaifenesin	O
100	O
mg/5	O
mL	O
Syrup	O
Sig:	O
Ten	O
(10)	O
ML	O
PO	O
Q4H	O
(every	O
4	O
hours).	O
8.	O
Aspirin	O
325	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
9.	O
Clotrimazole-Betamethasone	O
___	O
%	O
Lotion	O
Sig:	O
One	O
(1)	O
Topical	O
bid	O
().	O
10.	O
Enoxaparin	O
80	O
mg/0.8	O
mL	O
Syringe	O
Sig:	O
Seventy	O
(70)	O
mg	O
Subcutaneous	O
Q12H	O
(every	O
12	O
hours):	O
Please	O
continue	O
until	O
patient	O
is	O
seen	O
with	O
___	O
clinic	O
at	O
which	O
they	O
will	O
make	O
further	O
recommendations.	O
Discharge	O
Disposition:	O
Extended	O
Care	O
Facility:	O
___	O
Discharge	O
Diagnosis:	O
Primary:	O
Central	O
Retinal	I-Visual_impairment
Artery	B-Visual_impairment
Occlusion	B-Visual_impairment
Secondary:	O
Hypertension	O
GERD	O
Discharge	O
Condition:	O
Stable.	O
Patient	O
is	O
tolerating	O
oral	O
intake,	O
has	O
minimal	B-Visual_impairment
vision	B-Visual_impairment
from	O
right	O
eye,	O
and	O
has	O
clear	O
drainage	O
from	O
her	O
left-sided	O
nephrostomy	O
tube	O
site.	O
Discharge	O
Instructions:	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
further	O
management	O
after	O
loss	B-Visual_impairment
of	B-Visual_impairment
vision	B-Visual_impairment
in	O
your	O
right	O
eye.	O
At	O
Mass	O
Eye	O
and	O
Ear	O
you	O
were	O
found	O
to	O
have	O
a	O
central	O
retinal	B-Visual_impairment
artery	B-Visual_impairment
occlusion	B-Visual_impairment
which	O
caused	O
your	O
loss	B-Visual_impairment
of	B-Visual_impairment
vision.	B-Visual_impairment
You	O
should	O
follow	O
up	O
with	O
Dr.	O
___	O
in	O
neuroopthamology	O
at	O
___	O
Eye	O
and	O
Ear	O
for	O
further	O
management	O
___.	O
While	O
at	O
___,	O
we	O
could	O
not	O
find	O
a	O
source	O
for	O
your	O
blood	O
clot,	O
and	O
it	O
appears	O
that	O
you	O
have	O
developed	O
the	O
blood	O
clot	O
while	O
on	O
coumadin.	O
We	O
have	O
started	O
you	O
on	O
a	O
different	O
anticoagulant	O
called	O
lovenox,	O
which	O
you	O
should	O
continue	O
until	O
you	O
are	O
seen	O
in	O
___	O
clinic	O
by	O
Dr.	O
___	O
below).	O
You	O
should	O
follow	O
up	O
with	O
your	O
doctors	O
at	O
the	O
___	O
regarding	O
your	O
kidney.	O
We	O
made	O
the	O
following	O
changes	O
to	O
your	O
medications:	O
-	O
coumadin	O
-	O
This	O
medication	O
was	O
stopped.	O
-	O
lovenox	O
-	O
This	O
is	O
a	O
new	O
medication	O
to	O
help	O
prevent	O
further	O
blood	O
clots.	O
-	O
aspirin	O
-	O
This	O
is	O
a	O
new	O
medication	O
to	O
help	O
prevent	O
further	O
blood	O
clots.	O
Please	O
call	O
your	O
physician	O
or	O
return	O
to	O
the	O
hospital	O
if	O
you	O
develop	O
worsening	B-Visual_impairment
vision,	B-Visual_impairment
uncontrolled	O
bleeding,	O
lightheadedness,	O
palpitations,	O
chest	O
pain,	O
shortness	O
of	O
breath,	O
decreased	O
urine	O
output	O
or	O
any	O
other	O
concerning	O
symptoms.	O
Followup	O
Instructions:	O
___	O

